Posted by Michael Wonder on 04 May 2021
GSK’s Zejula is recommended for reimbursement by CADTH and INESSS for advanced ovarian cancer following response to first-line platinum-based chemotherapy
4 May 2021 - Zejula (niraparib) has received conditional positive recommendations for reimbursement from the Canadian Agency of Drugs and Technology in Health (CADTH) and L’Institut national d’excellence en santé et en services sociaux (INESSS), both Canadian health technology assessment bodies.
The organisations recommend reimbursement for Zejula for monotherapy maintenance treatment of female adult patients with newly diagnosed epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.
